THANZ/LinkedIn
Mar 13, 2026, 16:15
New Evidence From the COBRRA Trial in Acute VTE – THANZ
Thrombosis and Haemostasis Society of Australia and New Zealand (THANZ) shared a post on LinkedIn about a recent article by Lana A. Castellucci et al, published on NEJM:
“Congratulations to our THANZ members on a NEJM publication!
This international randomized trial (COBRRA) shows substantially lower bleeding risk with apixaban compared with rivaroxaban in acute VTE – evidence that matters at the bedside.”
Title: Bleeding Risk with Apixaban vs. Rivaroxaban in Acute Venous Thromboembolism
Authors: Lana A. Castellucci, Vivien M. Chen, Michael J. Kovacs, Alejandro Lazo-Langner, Peter Greenstreet, Susan Kahn, Benoit Côté
Read the Full Article on NEJM
Other posts featuring THANZ on Hemostasis Today.
-
Jun 14, 2026, 06:19Sharmila Manian: World Blood Donor Day – Where Generosity Meets Smart Medicine
-
Jun 14, 2026, 06:04Vishnu R.: FedServ Employees Unite to Save Lives Through Blood Donation
-
Jun 13, 2026, 20:28Tarun Tyagi: Translational Insights into Severe Immune Thrombocytopenia
-
Jun 13, 2026, 18:25Miguel Gómez Álvarez: Reviewing Inflammation, Transplantation, and Gene Therapy in Hemoglobinopathies
-
Jun 13, 2026, 18:24Ana Pedrero Gil: Why Factor XIII Deficiency Is Often Overlooked During Acute Bleeding
-
Jun 13, 2026, 18:23Tobias Degsell: Building Stronger Bridges Across Disciplines, Countries, and Perspectives at EHA 2026
-
Jun 13, 2026, 18:22Haemoglobinopathies, Innovation, Patient Experience, and Equitable Access at EHA 2026 – TIF
-
Jun 13, 2026, 18:21Thomas Stauch: Discussing the Future of ITP Research and Patient Care
-
Jun 13, 2026, 17:11Kim De Keersmaecker: Advancing Hematology Through Shared Expertise at EHA 2026